Confronto

Icatibant vs. Nafarelin

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

138614-30-9

nessun dato

Peso molecolare

1304.52 g/mol

nessun dato

Emivita

nessun dato

Sequenza

nessun dato

Meccanismo d'azione

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Nafarelin

Nafarelin is a potent GnRH agonist: after an initial stimulation ('flare'), continuous receptor occupancy leads to downregulation and thereby suppression of LH, FSH and the downstream sex hormones.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Icatibant	Nafarelin
Germania	Su prescrizione	Su prescrizione
Stati Uniti	Su prescrizione	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Icatibant and Nafarelin?: Icatibant is classified as "Ricerca (altro)", while Nafarelin is classified as "Ricerca (altro)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Nafarelin: Nafarelin is a GnRH agonist and the only member of this class delivered as a nasal spray. It is approved for treating endometriosis and central precocious puberty. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Icatibant or Nafarelin?: The highest available evidence level is "RCT sull'uomo" for Icatibant and "RCT sull'uomo" for Nafarelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Icatibant and Nafarelin in Germany and the United States?: Germania: Icatibant — Su prescrizione, Nafarelin — Su prescrizione. Stati Uniti: Icatibant — Su prescrizione, Nafarelin — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Icatibant

Nafarelin

Germania

Su prescrizione

Stati Uniti

Su prescrizione

Frequently asked questions

What is the difference between Icatibant and Nafarelin?

Icatibant is classified as "Ricerca (altro)", while Nafarelin is classified as "Ricerca (altro)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Nafarelin: Nafarelin is a GnRH agonist and the only member of this class delivered as a nasal spray. It is approved for treating endometriosis and central precocious puberty. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Icatibant or Nafarelin?

The highest available evidence level is "RCT sull'uomo" for Icatibant and "RCT sull'uomo" for Nafarelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Icatibant and Nafarelin in Germany and the United States?

Germania: Icatibant — Su prescrizione, Nafarelin — Su prescrizione. Stati Uniti: Icatibant — Su prescrizione, Nafarelin — Su prescrizione. These are factual summaries with source and review date on the individual pages.